Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of “Hold” by Brokerages

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $62.8333.

Several analysts have commented on the company. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Finally, Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th.

Supernus Pharmaceuticals Trading Up 8.5%

Shares of SUPN opened at $46.91 on Thursday. The company’s 50 day simple moving average is $46.14 and its 200-day simple moving average is $48.96. Supernus Pharmaceuticals has a 12-month low of $38.26 and a 12-month high of $59.68. The firm has a market cap of $2.73 billion, a PE ratio of -24.43, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Summit Global Investments acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $206,000. Handelsbanken Fonder AB grew its holdings in shares of Supernus Pharmaceuticals by 8.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 20,716 shares of the specialty pharmaceutical company’s stock worth $964,000 after acquiring an additional 1,700 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in Supernus Pharmaceuticals by 2.0% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 90,213 shares of the specialty pharmaceutical company’s stock worth $4,196,000 after purchasing an additional 1,759 shares during the last quarter. Empowered Funds LLC purchased a new stake in Supernus Pharmaceuticals during the first quarter worth $264,000. Finally, Bank of America Corp DE grew its holdings in Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.